Gossamer Bio (GOSS) Competitors

$0.21 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.21 +0.00 (+0.90%)

As of 05/22/2026 07:56 PM Eastern

GOSS vs. PALI, SOPH, ABEO, BCYC, and ORGO

Should you buy Gossamer Bio stock or one of its competitors? MarketBeat compares Gossamer Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gossamer Bio include Palisade Bio (PALI), SOPHiA GENETICS (SOPH), Abeona Therapeutics (ABEO), Bicycle Therapeutics (BCYC), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry.

How does Gossamer Bio compare to Palisade Bio?

Gossamer Bio (NASDAQ:GOSS) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 7.2% of Gossamer Bio shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Palisade Bio has lower revenue, but higher earnings than Gossamer Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.02	-$170.37M	-$0.79	N/A
Palisade Bio	$250K	1,353.92	-$16.78M	-$1.01	N/A

In the previous week, Gossamer Bio had 13 more articles in the media than Palisade Bio. MarketBeat recorded 21 mentions for Gossamer Bio and 8 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.67 beat Gossamer Bio's score of 0.06 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Gossamer Bio	Neutral
Palisade Bio	Positive

Palisade Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Palisade Bio	N/A	-36.79%	-34.34%

Gossamer Bio currently has a consensus price target of $5.00, suggesting a potential upside of 2,279.82%. Palisade Bio has a consensus price target of $10.20, suggesting a potential upside of 423.08%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Gossamer Bio has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Summary

Gossamer Bio beats Palisade Bio on 9 of the 17 factors compared between the two stocks.

How does Gossamer Bio compare to SOPHiA GENETICS?

Gossamer Bio (NASDAQ:GOSS) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Gossamer Bio has a beta of 2.15, meaning that its share price is 115% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

SOPHiA GENETICS has higher revenue and earnings than Gossamer Bio. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.02	-$170.37M	-$0.79	N/A
SOPHiA GENETICS	$77.27M	4.33	-$79M	-$0.52	N/A

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 7.2% of Gossamer Bio shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Gossamer Bio had 20 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 21 mentions for Gossamer Bio and 1 mentions for SOPHiA GENETICS. Gossamer Bio's average media sentiment score of 0.06 beat SOPHiA GENETICS's score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SOPHiA GENETICS has a net margin of -44.48% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Gossamer Bio presently has a consensus price target of $5.00, indicating a potential upside of 2,279.82%. SOPHiA GENETICS has a consensus price target of $7.50, indicating a potential upside of 53.69%. Given Gossamer Bio's higher possible upside, equities research analysts plainly believe Gossamer Bio is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Gossamer Bio beats SOPHiA GENETICS on 9 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Abeona Therapeutics?

Gossamer Bio (NASDAQ:GOSS) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Gossamer Bio currently has a consensus target price of $5.00, indicating a potential upside of 2,279.82%. Abeona Therapeutics has a consensus target price of $19.00, indicating a potential upside of 249.26%. Given Gossamer Bio's higher probable upside, equities research analysts plainly believe Gossamer Bio is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Abeona Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.02	-$170.37M	-$0.79	N/A
Abeona Therapeutics	$5.82M	53.27	$71.18M	$0.97	5.61

In the previous week, Gossamer Bio had 5 more articles in the media than Abeona Therapeutics. MarketBeat recorded 21 mentions for Gossamer Bio and 16 mentions for Abeona Therapeutics. Gossamer Bio's average media sentiment score of 0.06 beat Abeona Therapeutics' score of -0.35 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 7.2% of Gossamer Bio shares are held by company insiders. Comparatively, 6.9% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gossamer Bio has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Abeona Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Summary

Gossamer Bio beats Abeona Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Gossamer Bio has a net margin of -324.82% compared to Bicycle Therapeutics' net margin of -344.95%. Gossamer Bio's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Gossamer Bio	-324.82%	N/A	-96.10%

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 7.2% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bicycle Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market.

Gossamer Bio has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.35	-$218.96M	-$3.15	N/A
Gossamer Bio	$48.47M	1.02	-$170.37M	-$0.79	N/A

In the previous week, Gossamer Bio had 20 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 21 mentions for Gossamer Bio and 1 mentions for Bicycle Therapeutics. Gossamer Bio's average media sentiment score of 0.06 beat Bicycle Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	1 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bicycle Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 207.69%. Gossamer Bio has a consensus target price of $5.00, suggesting a potential upside of 2,279.82%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Gossamer Bio beats Bicycle Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Organogenesis has a net margin of -0.84% compared to Gossamer Bio's net margin of -324.82%. Organogenesis' return on equity of 9.63% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Gossamer Bio	-324.82%	N/A	-96.10%

Organogenesis currently has a consensus price target of $8.50, suggesting a potential upside of 219.55%. Gossamer Bio has a consensus price target of $5.00, suggesting a potential upside of 2,279.82%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Gossamer Bio had 19 more articles in the media than Organogenesis. MarketBeat recorded 21 mentions for Gossamer Bio and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.37 beat Gossamer Bio's score of 0.06 indicating that Organogenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	1 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 33.0% of Organogenesis shares are held by company insiders. Comparatively, 7.2% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Organogenesis has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.15, suggesting that its stock price is 115% more volatile than the broader market.

Organogenesis has higher revenue and earnings than Gossamer Bio. Organogenesis is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.61	$37.03M	-$0.19	N/A
Gossamer Bio	$48.47M	1.02	-$170.37M	-$0.79	N/A

Summary

Organogenesis and Gossamer Bio tied by winning 8 of the 16 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.31M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.27	18.74	20.99	25.66
Price / Sales	1.02	323.98	560.30	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-0.30	7.09	10.41	7.14
Net Income	-$170.37M	$24.45M	$3.57B	$335.98M
7 Day Performance	5.52%	6.38%	6.41%	4.15%
1 Month Performance	-42.07%	2.43%	3.55%	2.54%
1 Year Performance	-82.49%	62.98%	34.12%	35.06%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	2.7904 of 5 stars	$0.21 flat	$5.00 +2,279.8%	-82.5%	$49.31M	$48.47M	N/A	180	Gap Down
PALI Palisade Bio	2.299 of 5 stars	$1.81 -1.1%	$10.20 +463.5%	+141.6%	$317.65M	$250K	N/A	10	Gap Up
SOPH SOPHiA GENETICS	1.9715 of 5 stars	$4.69 +1.3%	$7.50 +59.9%	+71.2%	$317.09M	$81.18M	N/A	520
ABEO Abeona Therapeutics	2.4095 of 5 stars	$5.37 -2.2%	$19.00 +253.8%	-15.3%	$312.90M	$5.82M	5.54	90	Gap Up
BCYC Bicycle Therapeutics	3.0571 of 5 stars	$4.36 -2.0%	$14.00 +221.1%	-43.5%	$310.20M	$72.86M	N/A	240	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. PALI, SOPH, ABEO, BCYC, and ORGO

How does Gossamer Bio compare to Palisade Bio?

Summary

How does Gossamer Bio compare to SOPHiA GENETICS?

Summary

How does Gossamer Bio compare to Abeona Therapeutics?

Summary

How does Gossamer Bio compare to Bicycle Therapeutics?

Summary

How does Gossamer Bio compare to Organogenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. PALI, SOPH, ABEO, BCYC, and ORGO

How does Gossamer Bio compare to Palisade Bio?

Do insiders & institutionals hold more shares of GOSS or PALI?

Which has better valuation and earnings, GOSS or PALI?

Does the media favor GOSS or PALI?

Is GOSS or PALI more profitable?

Do analysts rate GOSS or PALI?

Which has more risk and volatility, GOSS or PALI?

Summary

How does Gossamer Bio compare to SOPHiA GENETICS?

Which has more risk and volatility, GOSS or SOPH?

Which has stronger valuation & earnings, GOSS or SOPH?

Do insiders and institutionals have more ownership in GOSS or SOPH?

Does the media refer more to GOSS or SOPH?

Is GOSS or SOPH more profitable?

Do analysts recommend GOSS or SOPH?

Summary

How does Gossamer Bio compare to Abeona Therapeutics?

Do analysts rate GOSS or ABEO?

Which has stronger earnings & valuation, GOSS or ABEO?

Does the media favor GOSS or ABEO?

Do insiders & institutionals believe in GOSS or ABEO?

Which has more risk and volatility, GOSS or ABEO?

Is GOSS or ABEO more profitable?

Summary

How does Gossamer Bio compare to Bicycle Therapeutics?

Is BCYC or GOSS more profitable?

Do institutionals & insiders have more ownership in BCYC or GOSS?

Which has more risk and volatility, BCYC or GOSS?

Which has preferable valuation & earnings, BCYC or GOSS?

Does the media prefer BCYC or GOSS?

Do analysts prefer BCYC or GOSS?

Summary

How does Gossamer Bio compare to Organogenesis?

Is ORGO or GOSS more profitable?

Do analysts rate ORGO or GOSS?

Does the media refer more to ORGO or GOSS?

Do insiders & institutionals hold more shares of ORGO or GOSS?

Which has more volatility & risk, ORGO or GOSS?

Which has preferable valuation & earnings, ORGO or GOSS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools